The first biologic agent used in the treatment of MS was IFN-β, followed by glatiramer-acetate, monoclonal antibodies, fingolimod, and others (Rommer et al., 2019; Li et al., 2020). This evidence concerns the gene IFNB1 and myeloid sarcoma.